Sep 24, 2020



Most Recent Coverage:

Doctrin, a Stockholm, Sweden-based telehealth platform provider, will be receptive to investor approaches next year, said Carlos Lorente, co-founder and CFO. (Please click on the hyperlink above to read this article)

Brief Summary:

Doctrin's digital platform automates a patient's journey and can integrate with medical records, allowing patients to make physical or chat-based appointments.

Investors:

Capio, Swedbank Robur, HealthCap, Inbox Capital, Norrsken Foundation

CFO and co-founder:

Carlos Lorente









Paige, a New York-based computational pathology company, is seeking strategic partners after its recent capital raise, said Carla Leibowitz, Chief Business Development Officer. (Please click on the hyperlink above to read this article)

Brief Summary:

The company has already received its CE Mark and FDA 510(k) clearance for FullFocus, its digital pathology image viewer. However, it is awaiting FDA approval for the use of FullFocus for prostate cancer detection, which is likely early next year, said Leibowitz.

Investors:

Goldman Sachs Merchant Banking Division, Healthcare Venture Partners, Breyer Capital and Kenan Turnacioglu

CEO:

Leo Grady









**Pactiv Surgical*, a Boston, Massachusetts-based surgical software startup, will raise its Series B in early 2021, said Todd Usen, CEO. (Please click on the hyperlink above to read this article)

Brief Summary:

Activ Surgical's ctivEdge platform uses sensors to collect real-time data during surgeries. Its first product, ActivSight, a small connected imaging coddle that attaches to laparoscopic surgical instruments, is focused on real-time blood flow. It will submit for FDA approval this fall and expects FDA clearance by Q1 2021.

Advisors:

Wilson Sonsini

Investors:

ARTIS Ventures, LRVHealth, DNS Capital, GreatPoint Ventures, Tao Capital Partners and Rising Tide VC

CEO:

Todd Ulsen





Interesting Fact:

Usen, a thirty year medtech veteran, joined Activ Surgical in January 2019 to scale and grow the company. He previously served as the President of the Medical Systems Group at Olympus Corporation of the Americas. He was also the President of Orthopedics, at Smith and Nephew, overseeing the Total Joint, Sports Medicine and Trauma divisions. He received his B.S. in Marketing from the University of Massachusetts Isenberg School of Business and did his M.B.A. work at Pepperdine University.





WhizAI, a Somerset, New Jersey-based provider of an Al-driven business intelligence platform for pharma and life sciences companies, is planning its Series A raise in 12 months, said Rohit Vashisht, co-founder and CEO. (Please click on the hyperlink above to read this article)

Brief Summary:

The company's artificial intelligence platform for pharmaceutical and life sciences uses natural language processing and cognitive insights to answer user's questions via voice and text.

Investors:

Healthy Ventures, Bling Capital, Firebolt Ventures

CEO and co-founder:

Rohit Vashisht





Interesting Fact:

Vashisht is actively seeking strategic partnerships and welcomes approaches, he said. As it builds its partner network, it is interested in partnering with system integrators, data partners, technology players such as Viva Technology and Salesforce, and platform companies such as Amazon Web Services or Google. It will consider reseller agreements and other deal structures.





**Sprout Therapy, a San Francisco-based autism-focused healthtech company, is planning for another capital raise in Q4 2020 or Q1 2021, said Yury Yakubchyk Jr., co-founder and CEO. (Please click on the hyperlink above to read this article)

Brief Summary:

Sprout is a healthtech platform that offers personalized autism therapy programs designed by therapists for families and can be administered both in person and online.

Investors:

General Catalyst, Felicis Ventures and Bling Capital

CEO and co-founder:

Yury Yakubchyk Jr.

Interesting Fact:

International expansion is also on its radar with Canada and Western Europe likely in 2021 or 2022. China and Japan are also markets with earlier-stage autism therapies and Sprout could have a significant impact in those countries, Yakubchyk told FHM..





♥InformAI, a Houston, Texas-based healthcare analytics company, is gearing up for a Series A raise in Q4 this year, said Jim Havelka, CEO. (Please click on the hyperlink above to read this article)

Brief Summary:

The InformAI Sinus Image Classifier is a diagnostic-assist tool that assists physicians in three ways: evaluating sinus medical conditions at the point of care, speeding up radiologist workflow by flagging medical conditions for further review and providing a triage of pending sinus patient study reviews, according to the company.

Investors:

DEFTA Partners, Joyance Partners and Social Starts

CEO:

Jim Havelka





Interesting Fact:

As long as InformAl adheres to its plans, it expects a post Series A valuation ranging between \$25m and \$40m. It expects its valuation to grow as it launches its Sinus Image Classifier in the market, receives approvals for its pending patents and demonstrates success of its Al-enabled classifiers in the market, Havelka told FHM.





**Trusty.care*, a New York-based startup providing an Al-driven platform which helps to find the best Medicare Advantage, supplemental, and drug plans for retirees, is near closing a seed round extension with an aim to raise its Series A in Q1 of next year, CEO Jo Schneier said. (Please click on the hyperlink above to read this article)

Brief Summary:

Trusty.care's digital platform helps identify the right health insurance products, public benefits and cost savings tools for people who are in retired.

Co-founder:

Gerard Carey





Interesting Fact:

Everyday 10,000 people in the US turn 65 years old and are in need of Medicare and health insurance products, which is the case even in a recession, the CEO said. As a result, Trusty.care does not expect to be as negatively affected by an economic downturn as many other businesses. Amid the pandemic, brokers and advisors seem to be getting pushed towards digital customer interaction rather than in-person meetings, which could actually accelerate business for Trusty.care, Schneier said.





Chacadoo, the Zurich, Switzerland-based digital health technology company, is on the lookout for acquisitions and strategic partnerships, said Peter Ohnemus, CEO and founder. (*Please click on the hyperlink above to read this article*)

Brief Summary:

dacadoo offers two products to its customers. Its real-time Health Score makes health individually measurable through an engaging user experience that also allows its enterprise customers to effectively measure the health impact of wellness programs, according to the company. Its second product, RESTful API, allows its customers to create their own customized user journeys and client-facing applications.

Advisors:

Kempen & Co

CEO and founder:

Peter Ohnemus



Interesting Fact:

Prior to founding dacadoo, Ohnemus founded ASSET4 which he sold to Reuters in 2009. He also held roles at Sybase, Logic Works, The Fantastic Corporation and COS, all of which had successful IPOs during his time at each company. Ohnemus has five daughters.





POPS! Diabetes Care, a Minneapolis, Minnesota-based diabetes management app provider, is raising a bridge round now and expects to seek its Series B next year, said Lonny Stormo, cofounder. (*Please click on the hyperlink above to read this article*)

Brief Summary:

The company's goal is to deliver better solutions to allow people to manage chronic health conditions on the go. Its first product targets type 1 diabetes as most of the time people with diabetes do not carry their insulin supplies with them.

Investors:

30Ventures, Revolution's Rise of the Rest Seed Fund and Flying Point Industries

co-founder:

Lonny Stormo





Interesting Fact:

In 2013, Stormo, Dan Davis, and Curt Christensen came up with the idea for POPS! while fishing on a remote lake in Minnesota. While Stormo was watching Davis reel in a large walleye at the same time as trying to check his blood sugar levels with a testing kit, Stormo asked his friends, "Why can't I check my blood sugar while fishing or jogging on my phone?" The idea for POPS! was born and the three co-founders engineered an all-in-one meter, which is now launched in the market.





Pareto Intelligence, a Chicago-based healthcare analytics company, is exploring strategic partnerships and acquisitions to fuel growth, said Jason Montrie, president. (Please click on the hyperlink above to read this article)

Brief Summary:

Pareto analyzes claims and medical costs through proprietary algorithms, predictive models, and advanced data science.

CEO:

John Steele





Interesting Fact:

COVID-19 will also create acquisition opportunities as the market remains challenging, the executive noted. Well run companies that help Pareto go deeper into its existing markets to more broadly serve its customers would be interesting to Pareto.





Picwell, a Philadelphia, Pennsylvania-based employee benefits healthtech, is evaluating sale and capital raise options, said Matthew Sydney, CEO. (Please click on the hyperlink above to read this article)

Brief Summary:

Picwell DX is a direct to consumer and allows individual employees to see which health plan best fits their personal situation. Picwell API is the company's commercial or direct to business product that helps human resource and employee benefit departments present employees with a ranking of plan fit.

Investors:

Sandbox Ventures, MassMutual Ventures and Aflac

CEO:

Matthew Sydney





Interesting Fact:

Sydney joined Picwell in 2017. He previously held a sales executive role at Utah-based HealthEquity, a health savings company. Picwell was founded in 2013 by a group of University of Pennsylvania professors and a Wharton MBA.





Fellipsis Health, a San Francisco-based behavioral health technology startup, will probably look to raise its Series A later this year, a source familiar with the company said. (*Please click on the hyperlink above to read this article*)

Brief Summary:

The company's app helps clinicians identify those at risk of anxiety and depression and also provides ongoing support to help providers understand a patient's condition over time. The company's machine-learning algorithms consider several metrics of speech and are able to assess a patient's condition within minutes of that patient responding to questions via the app.

Investors:

Khosla Ventures

CEO:

Dr. Cory Kidd





Interesting Fact:

Ellipsis has set a benchmark to beat the current standard for detecting depression in claims analysis and by primary care providers (PCPs). Ellipsis can detect depression in about 60% of cases which is better than existing methodologies, the source said.





PMDI Health, an Al-powered healthtech company developing an algorithm-based system to help clinicians identify populations at risk of Medication Related Problems, is looking to raise its seed round, co-founder and CEO Avishai Ben-Tovim told this news service. (Please click on the hyperlink above to read this article)

Brief Summary:

MDI Health is developing an algorithm-based system to help clinicians identify populations at risk of Medication Related Problems (MRPs). The company draws data and considers itself an add-on product to electronic health record (EHRs) systems.

Investors:

Jumpspeed and Fresh.Fund

CEO:

Avishai Ben-Tovim





Interesting Fact:

A potential universe of buyers could eventually include large EHRs companies, businesses with large drug databases, Pharmacogenomics firms and those attempting to provide precision medicine, the CEO said.





MyDoc, a Singapore-based digital healthcare startup, is starting conversations for its next capital raise, said Snehal Patel, CEO and co-founder. (*Please click on the hyperlink above to read this article*)

Brief Summary:

MyDoc is a digital healthcare platform that aims to control costs of health insurance premiums,. Its mobile app allows patients to monitor their acute, chronic and preventive medical care needs. The app allows users to track health data, view medical screening results, access video chats with physicians 24/7, and refill prescriptions.

CEO and co-founder:

Dr. Snehal Patel





Interesting Fact:

A sale to a strategic is a more likely exit option than an IPO, Patel said. It has had some "soft" conversations with potential acquirers who offer synergistic services; however, MyDoc expects those options are at least three to five years away as it is aiming for "massive traction" in both the US and UK markets over the next two years.

₩ DeepScribe



Most Recent Coverage:

PeepScribe, a San Francisco-based company using Al and natural language processing to reduce time spent on electronic health record (EHR) documentation could be in a position to open its A round towards the end of 2020, COO and cofounder Matthew Ko said. (Please click on the hyperlink above to read this article)

Brief Summary:

DeepScribe has developed a product to reduce the amount of time health care professionals spend on EHR documentation. Powered by Al/NLP, this product can passively listen to natural patient conversations and complete documentation for the physicians, leading to less errors and overall physician burnout.

Investors:

Bee Partners, Supernode Ventures, Tsingyuan Ventures, Plug and Play, Berkeley Skydeck, 1984, and Wavemaker Three-Sixty Health

CEO and co-founder:

Akilesh Bapu





Interesting Fact:

DeepScribe developed its techniques in the Berkeley Al Research lab and it is able to build its models with 10x less data than its competitors, according to company information.

Mar 03, 2020





Most Recent Coverage:

CompanionMX, a Boston-based digital health company specializing in communication analysis for mental health monitoring, will be seeking strategic partnerships, acting CEO Victoria Smith said. (*Please click on the hyperlink above to read this article*)

Brief Summary:

The CompanionTM system uses active monitoring of vocal features and passive monitoring of smartphone metadata to compute real-time behavioral biomarkers of mood and anxiety disorders, according to company information. The company completes voice analysis and digital phenotyping to analyze how people communicate, not what they say, Smith said.

Investors:

Cogito

CEO:

Victoria Smith





Interesting Fact:

In addition to her position as acting CEO of CompanionMx, Smith is Head of Clinical Development at Cogito which she joined in 2016. She has a background in clinical research holding previous positions at Atlas5D, a medical device company, and Massachusetts General Hospital.

QRfertile



Most Recent Coverage:

**QRFertile, a Farmington, Connecticut-based company developing a home use men's fertility test and an accompanying telemedicine application, is amid a seed round, CEO and co-founder Reza Amin said. (Please click on the hyperlink above to read this article)

Brief Summary:

QRfertile is developing an over-the-counter fertility test that men will be able to buy in a pharmacy and use in the comfort of their home. In addition to the test, the company is also developing a mobile telemedicine application which will connect test users to physicians, who will provide fertility recommendations on the spot.

CEO and co-founder:

Reza Amin





Interesting Fact:

The company is already in discussions with some potential distribution partners as well as urologists and gynecologists stakeholders, who could also be future distribution partners, Amin said. It is also amid some conversations with insurance companies regarding future collaborations. Integration with payers will be key to the company's long-term expansion; although initially, its test won't be directly tied to payers, Amin said. In the future, QRfertile envisions a B2B model where the company would provide men's health services through employee benefits packages, he said.



**BrainCheck*, a Houston, Texas-based medtech company providing cognitive assessment tools, is planning to raise its Series B in 2021 after hitting some milestones but is now open to investor conversations, CEO and co-founder Yael Katz said. (Please click on the hyperlink above to read this article)

Brief Summary:

BrainCheck provides gamified neurocognitive tests that can be administered on iPad, iPhone and computers. Its tools, which are reimbursable by insurance and HIPAA compliant, are used in over 200 clinical practices and by 100,000 individual users.

Investors:

S3 Ventures, Tensility Venture Partners, True Wealth Ventures and Nueterra Capital

CEO and co-founder:

Yael Katz





Interesting Fact:

In 10 minutes, BrainCheck can assess a wide-range of cognitive domains, including reaction time, immediate and delayed recall, cognitive processing, executive function, visual attention, task switching, and coordination.

© clearstep



Most Recent Coverage:

Clearstep, a Chicago, Illinoise-based Al-driven consumer healthcare recommendation platform, is seeking its seed round, CEO and co-founder Adeel Malik said. (Please click on the hyperlink above to read this article)

Brief Summary:

Clearstep is not designed to be a direct-to-consumer product. The platform is branded, configured, and licensed to healthcare providers and payers.

CEO:

Adeel Malik







PLINEUS Medical, a Fayetteville, Arkansas-based medical device company whose flagship product is Safebreak Vascular, designated as a class II De Novo device, is now seeking more capital, CTO and founder Spencer Jones told this news service. (Please click on the hyperlink above to read this article)

Brief Summary:

Safebreak Vascular, designated as a class II De Novo device, is the company's flagship product. It is a patented "break-away" mechanism that fits into all standard IV lines which will fit inbetween a patient's catheter and the IV pump/bag. The product is designed to stop an IV from getting dislodged (e.g. pulled out) of a patient because the device will separate at 3.7 pounds of force.

Investors:

Innova, MB Venture Partners, F&S Capital

Interesting Fact:

Prior to founding Lineus, Jones was a registered nurse. He became frustrated when patients he cared for dislodged their IVs. He decided to design a new product to solve the problem.





PEncapsulate, a Farmington, Connecticut-based startup developing an automated tumor-on-achip system that can grow patients' cancer cells outside the body, is seeking seed capital, CEO and co-founder Armin T. Rad said. (*Please click on the hyperlink above to read this article*)

Brief Summary:

The company is developing an automated tumor-on-a-chip system that can grow patients' cancer cells outside the body and test the efficacy of chemotherapeutic drugs against them to advocate for the best course of treatment.

CEO and co-founder:

Armin T. Rad





Interesting Fact:

Encapsulate has started pilot studies with UConn for lung cancer. It is seeking to work with Hartford HealthCare for a second type of cancer, which most likely will be colorectal cancer, Rad said during his Demo.

**PInterRemit (Financial Technology Applications Inc), a Bay Area startup whose software helps businesses find the optimal FX rate for large cross-border money transfers by using cryptocurrencies, could seek seed funding in a few months, CEO Christos Stoumpos told this news service. (Please click on the hyperlink above to read this article)

Brief Summary:

a Bay Area startup whose software helps businesses find the optimal FX rate for large cross-border money transfers by using cryptocurrencies

